![CHEST on X: "Cefepime-associated neurotoxicity is uncommon, but critically ill patients with renal dysfunction may be at greater risk. Read more: https://t.co/hrXXhwftyz #journalCHEST #CHESTCritCare https://t.co/hVLDyYJH8X" / X CHEST on X: "Cefepime-associated neurotoxicity is uncommon, but critically ill patients with renal dysfunction may be at greater risk. Read more: https://t.co/hrXXhwftyz #journalCHEST #CHESTCritCare https://t.co/hVLDyYJH8X" / X](https://pbs.twimg.com/media/EcquhJVX0AMdbld.jpg:large)
CHEST on X: "Cefepime-associated neurotoxicity is uncommon, but critically ill patients with renal dysfunction may be at greater risk. Read more: https://t.co/hrXXhwftyz #journalCHEST #CHESTCritCare https://t.co/hVLDyYJH8X" / X
![PDF] Cefepime neurotoxicity: thresholds and risk factors. A Retrospective Cohort study. | Semantic Scholar PDF] Cefepime neurotoxicity: thresholds and risk factors. A Retrospective Cohort study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f701d4b2c61690c9d2a60293bec243371d89706b/20-Table1-1.png)
PDF] Cefepime neurotoxicity: thresholds and risk factors. A Retrospective Cohort study. | Semantic Scholar
![Frontiers | Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants Frontiers | Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants](https://www.frontiersin.org/files/Articles/496035/fphar-11-00014-HTML/image_m/fphar-11-00014-t001.jpg)
Frontiers | Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
![Prospective monitoring of cefepime in intensive care unit adult patients | Critical Care | Full Text Prospective monitoring of cefepime in intensive care unit adult patients | Critical Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fcc8941/MediaObjects/13054_2009_Article_8371_Fig1_HTML.jpg)
Prospective monitoring of cefepime in intensive care unit adult patients | Critical Care | Full Text
![Antibiotics | Free Full-Text | Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients Antibiotics | Free Full-Text | Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients](https://www.mdpi.com/antibiotics/antibiotics-12-00996/article_deploy/html/images/antibiotics-12-00996-g001.png)
Antibiotics | Free Full-Text | Outcomes of Intravenous Push versus Intermittent Infusion Administration of Cefepime in Critically Ill Patients
Cefepime Dosing in Modeled Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies
![PDF] Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. | Semantic Scholar PDF] Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4a8e1916cdfcf9e32d7343db029b8a95e5caa58c/4-Table1-1.png)
PDF] Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. | Semantic Scholar
SUPPORTING EVIDENCE FOR ALTERNATE CEFEPIME DOSING SUBSTITUTION BACKGROUND Cefepime (CEP) is approved by the Food and Drug Admins
![The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections | Semantic Scholar The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8fb0d528dac3a383333689b4e301a9bf0ecd8e02/2-Table2-1.png)
The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections | Semantic Scholar
![Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens - ScienceDirect Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0924857917302005-antage5140-fig-5001.jpg)